This article is more than 5 years old. Information may no longer be current.

VIDEO: Intercept Pharmaceuticals VP discusses EASL guidelines for PBC

AMSTERDAM — In this exclusive video from International Liver Congress, Rick Lones, vice president, head of medical affairs for Europe, Canada and Australia at Intercept Pharmaceuticals, discusses EASL’s recently published 2017 guidelines for the management of primary biliary cholangitis.

“It’s ... been fantastic this week to see the first new guidelines produced by EASL in the last 9 years,” Lones said. “These provide some very clear guidance in terms of managing PBC based on all the latest evidence and really reflecting a very clear patient-centric approach, which will ensure that all patients are optimally managed and we can really drive better outcomes for this condition with very high unmet medical need.”

Disclosure: Lones is employed by Intercept Pharmaceuticals.